Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

Think of the heart as a pump that works tirelessly every day. But sometimes, this pump starts to weaken, which is what ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

such as sleep apnea. Share on Pinterest Trazodone is a prescription medication approved by the Food and Drug Administration (FDA) for depression. One of its key actions is regulating the ...

The Apple Watch Series 10 brings a few new features, including sleep apnea detection, but is it worth the upgrade? Read the review to learn more.

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire,” or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...